Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Colitis 2Urogenital Neoplasms 1Melanoma 1Lung Neoplasms 1Hepatitis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 3fludarabine 3aldesleukin 3Cyclophosphamide 3cabozantinib 2Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Fecal Microbiota Transplantation 2CTLA-4 Antigen 2vedolizumab 1prednylidene 1olaparib 1gallium 68 PSMA-11 1enfortumab vedotin 1deltacortene 1darolutamide 1Therapeutics 1Standard of Care 1Radiosurgery 1Radiation Dose Hypofractionation 1Prednisone 1Practice Guidelines as Topic 1Pluvicto 1Mitomycin 1Lutetium-177 1Lutetium 1Loperamide 1LDP-02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × vedolizumab × 90 days × Clear all
NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
800 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡